Skip to main content
Industry News
FDA grants devimistat fast track pancreatic cancer tag

The FDA fast tracked Rafael Pharmaceuticals' CPI-613, or devimistat, as a treatment for pancreatic cancer, the company announced. Devimistat has also received the orphan drug tag to treat myelodysplastic syndrome, acute myeloid leukemia, Burkitt lymphoma, peripheral T-cell lymphoma and soft tissue sarcoma.

Full Story: